Recent Patents on Drugs Addressing Neurodegenerative Diseases
Manuel Van Gijsel-Bonnello, Michel Khrestchatisky, Max de Reggi and Bouchra Gharib
Affiliation: NICN, UMR CNRS 7259, Faculty of Medicine, Aix-Marseille Univ., 15 Blvd Pierre Dramard, 13015 Marseille, France.
Keywords: Neurodegenerative diseases, new therapeutic strategies, patents, therapy, experimental autoimmune encephalomyelitis, neuroinflammation, infiltrating leukocytes, Cholinesterase inhibitors, Growth factor-like proteins, Cannabinoid receptors, MITOCHONDRIAL DYSFUNCTION, Pyrimidine nucleotide precursor
Considerable evidence gained in the past decade has supported a better understanding and management of neurodegenerative
diseases, in the face of the continuous increase of their prevalence in the world. Inflammation, mitochondrial
dysfunction and oxidative stress are now recognized to be hallmarks of all neurological disorders. Along with therapies
targeting these features, new therapeutic strategies are emerging, based on microRNA, vaccination, generation and
graft of neurons, as well as therapies based on multifaceted drugs. Are also taken into account vectors designed to deliver
large molecule pharmaceuticals or genes across the blood-brain barrier. Current treatments are mainly symptomatic, therefore
it is hoped that therapies based on patents described in the present review will lead to really curative treatments.
Rights & PermissionsPrintExport